The three eras: analog, digital and AI
Growing up across the analog, the digital and the AI worlds: a reflection on the vertigo, the risks and the opportunity of this new era, and on how it is changing the way we do research.
Computational drug discovery
I design them with computational tools and artificial intelligence: peptides, vaccines and de novo drugs, combining molecular dynamics, virtual screening and generative AI. And I write about what that work means.
Growing up across the analog, the digital and the AI worlds: a reflection on the vertigo, the risks and the opportunity of this new era, and on how it is changing the way we do research.
Yamanaka-factor partial reprogramming reduces the aging-associated “mesenchymal drift” and rejuvenates the transcriptome of human cells and tissues.
2025-08-15 Nature MedicineRentosertib, the first AI-discovered and AI-designed drug, improves lung function in idiopathic pulmonary fibrosis (phase IIa trial).
2025-06-03 NEJMFirst personalized CRISPR therapy (“N-of-1”): a baby with a lethal metabolic disorder (CPS1 deficiency), treated with base editing.
2025-05-15 NEJMTwice-yearly lenacapavir injections achieve near-100% protection against HIV in women (PURPOSE 1 trial).
2024-07-24 NatureAlphaFold 3, DeepMind's AI model, predicts the joint structure of proteins with ligands, nucleic acids and ions, outperforming specialised docking tools.
2024-05-08